Keyphrases
Type 2 Diabetic Patients
100%
Glucagon-like
100%
Dose-response
100%
Recombinant
100%
Glucagon-like peptide-1 (GLP-1)
100%
Amides
83%
Placebo
66%
Continuous Subcutaneous Infusion
33%
Blood Glucose
33%
Continuous Improvement
16%
Fasting C-peptide
16%
Type 2 Diabetes Mellitus (T2DM)
16%
Hypoglycemia
16%
Amide Group
16%
Glycemic Control
16%
Fasting Plasma Glucose
16%
Glucose Area under the Curve
16%
Dose-response Relationship
16%
Safety Concerns
16%
Glucose Profile
16%
High Dose
16%
Placebo-controlled Trial
16%
Dose-ranging
16%
Increased Dose
16%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Glucagon-Like Peptide-1
100%
Glucagon Like Peptide 1 [7-36] Amide
100%
Recombinant Glucagon
100%
Placebo
83%
Subcutaneous Injection
33%
Hypoglycemia
16%
Dose-Response Relationship
16%
C Peptide
16%